» Articles » PMID: 15286726

Helping the CD8(+) T-cell Response

Overview
Journal Nat Rev Immunol
Date 2004 Aug 3
PMID 15286726
Citations 340
Authors
Affiliations
Soon will be listed here.
Citing Articles

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.

Wu S, Ho C, Yang J, Yu S, Lin Y, Lin S Clin Transl Med. 2024; 15(1):e70149.

PMID: 39715697 PMC: 11666332. DOI: 10.1002/ctm2.70149.


Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model.

Alsalloum A, Alrhmoun S, Perik-Zavosdkaia O, Fisher M, Volynets M, Lopatnikova J Front Immunol. 2024; 15:1507218.

PMID: 39660132 PMC: 11628372. DOI: 10.3389/fimmu.2024.1507218.


Quantification of heterogeneity in human CD8 T cell responses to vaccine antigens: an HLA-guided perspective.

Harris D, Shanker A, Montoya M, Llewellyn T, Matuszak A, Lohar A Front Immunol. 2024; 15:1420284.

PMID: 39624092 PMC: 11608996. DOI: 10.3389/fimmu.2024.1420284.


Allorecognition Unveiled: Integrating Recent Breakthroughs Into the Current Paradigm.

Charmetant X, Pettigrew G, Thaunat O Transpl Int. 2024; 37:13523.

PMID: 39588197 PMC: 11586167. DOI: 10.3389/ti.2024.13523.


Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression.

Roerden M, Castro A, Cui Y, Harake N, Kim B, Dye J J Immunother Cancer. 2024; 12(11).

PMID: 39521615 PMC: 11552027. DOI: 10.1136/jitc-2024-010249.